
Diabetic patients with ovarian cancer who took the drug metformin for their diabetes had a better survival rate than patients who did not take it. When Mayo Clinic researchers analyzed factors such as the patients’ body mass index, the severity of the cancer, type of chemotherapy and quality of surgery, they found that patients taking metformin were nearly four times likelier to survive, compared with those not taking the medication. The results may pave the way for using metformin in large-scale randomized trials in ovarian cancer. Click here for news release
Cancer affects people worldwide, regardless of age, gender or socioeconomic status. That's why Mayo Clinic joins the Union for International Cancer Control and other global organizations on World Cancer ...
BARRON, Wis. — Preventive health screenings are important for everyone, yet these simple and routine things are not readily available to some. Nothing in life ...
Cancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In the last three ...